MARKET

NRBO

NRBO

NeuroBo Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.57
+0.41
+2.90%
Closed 16:00 03/27 EDT
OPEN
14.50
PREV CLOSE
14.16
HIGH
14.60
LOW
14.18
VOLUME
2.89K
TURNOVER
--
52 WEEK HIGH
36.22
52 WEEK LOW
5.95
MARKET CAP
8.67M
P/E (TTM)
-0.0241
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NRBO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NRBO stock price target is 2.000 with a high estimate of 2.000 and a low estimate of 2.000.

EPS

NRBO News

More
  • SPCE, I, FLR and WWR among midday movers
  • Seeking Alpha - Article · 02/18 17:40
  • INO, RDFN, SPWR and NUS among midday movers
  • Seeking Alpha - Article · 02/13 17:41
  • Mid-Morning Market Update: Markets Open Lower; PepsiCo Tops Q4 Views
  • Benzinga · 02/13 15:24
  • NeuroBo up 81%
  • Seeking Alpha - Article · 02/12 20:39

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About NRBO

NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. The Company is focused on developing pharmaceuticals to treat neurodegenerative disorders. The Company is addressing unmet needs in patients with Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease. The Company’s product candidate, NB-01, is targeting neuropathic pain with an indication in PDN. The Company also provides NB-02, which is an Alzheimer’s and tauopathies drug.
More

Webull offers kinds of Neurobo Pharmaceuticals Inc stock information, including NASDAQ:NRBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRBO stock news, and many more online research tools to help you make informed decisions.